Abstract
In New Delhi, India, candidemia affected 15 critically ill coronavirus disease patients admitted to an intensive care unit during April-July 2020. Candida auris accounted for two thirds of cases; case-fatality rate was high (60%). Hospital-acquired C. auris infections in coronavirus disease patients may lead to adverse outcomes and additional strain on healthcare resources.
Keywords:
2019 novel coronavirus disease; COVID-19; Candida auris; India; SARS-CoV-2; antimicrobial resistance; co-infection; coronavirus disease; nosocomial infection; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
MeSH terms
-
Adult
-
Aged
-
Antifungal Agents / therapeutic use
-
Betacoronavirus*
-
COVID-19
-
COVID-19 Drug Treatment
-
Candida*
-
Candidiasis / drug therapy
-
Candidiasis / epidemiology
-
Candidiasis / virology*
-
Coronavirus Infections / drug therapy
-
Coronavirus Infections / epidemiology
-
Coronavirus Infections / microbiology*
-
Critical Illness
-
Cross Infection / drug therapy
-
Cross Infection / epidemiology
-
Cross Infection / microbiology*
-
Drug Resistance, Multiple
-
Female
-
Humans
-
India / epidemiology
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Pandemics
-
Pneumonia, Viral / drug therapy
-
Pneumonia, Viral / epidemiology
-
Pneumonia, Viral / microbiology*
-
SARS-CoV-2